Skip to content

Study · Animal study (in vivo) · rat · 1995

4 results

Mechanism of action of hexarelin and GHRP-6: analysis of the involvement of GHRH and somatostatin in the rat.

Conley LK, Teik JA, Deghenghi R, Imbimbo BP, Giustina A, Locatelli V, Wehrenberg WB

Neuroendocrinology1 Jan 1995Cited by 29 (Europe PMC)

PMID7731497 (opens in a new tab)DOI10.1159/000126826 (opens in a new tab)PepBankPUB-07731497
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats pretreated with control antiserum, hexarelin produced a peak plasma GH of 552 ng/ml.

    In plain wordsIn rats given control antiserum, hexarelin raised growth hormone to a peak of 552 ng/ml.

    Peptide
    Hexarelin
    Outcome
    IncreasePeak plasma GH after hexarelin, control antiserum pretreatment
    Study

    ratn: not reported in source

    Adult male rats with jugular catheters
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    25 micrograms/kg · intravenous · single doseAs given in this study (rat).

    Measurements

    Peak plasma GH
    552 ng/ml
    hexarelin after control antiserum

    Source sentences

    Summary
    The peak plasma GH responses in rats pretreated with CTLas were 552 +/- 125 ng/ml following hexarelin administration and 386 +/- 132 ng/ml following GHRP-6 administration.
    2 context sentences
    Summary · context
    Animals were then treated i.v. with 25 micrograms/kg of either hexarelin or GHRP-6 4 h after i.v. antisera pretreatment.
    Summary · context
    In the present study, we have examined the neuroendocrine mechanism by which hexarelin and GHRP-6, two GH-releasing peptides, mediate their actions.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats pretreated with control antiserum, GHRP‑6 produced a peak plasma GH of 386 ng/ml.

    In plain wordsIn rats given control antiserum, GHRP‑6 raised growth hormone to a peak of 386 ng/ml.

    Peptide
    GHRP-6
    Outcome
    IncreasePeak plasma GH after GHRP-6, control antiserum pretreatment
    Study

    ratn: not reported in source

    Adult male rats with jugular catheters
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    25 micrograms/kg · intravenous · single doseAs given in this study (rat).

    Measurements

    Peak plasma GH
    386 ng/ml
    GHRP-6 after control antiserum

    Source sentences

    Summary
    The peak plasma GH responses in rats pretreated with CTLas were 552 +/- 125 ng/ml following hexarelin administration and 386 +/- 132 ng/ml following GHRP-6 administration.
    2 context sentences
    Summary · context
    Animals were then treated i.v. with 25 micrograms/kg of either hexarelin or GHRP-6 4 h after i.v. antisera pretreatment.
    Summary · context
    In the present study, we have examined the neuroendocrine mechanism by which hexarelin and GHRP-6, two GH-releasing peptides, mediate their actions.

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 03AnimalNot a test of Hexarelin aloneAnimal study (in vivo)Efficacy outcome

    In rats pretreated with somatostatin antiserum, the peak GH response to hexarelin was similar to that in control antiserum rats.

    In plain wordsIn rats given somatostatin antiserum, hexarelin raised growth hormone about as much as in rats given control antiserum.

    Peptide
    Hexarelin
    Outcome
    No significant changePeak plasma GH after hexarelin, somatostatin antiserum pretreatment
    Study

    ratn: not reported in source

    Adult male rats with jugular catheters
    Comparator
    Control antiserum pretreatment
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Peak plasma GH
    702 ng/ml
    hexarelin after somatostatin antiserum

    Source sentences

    Summary
    Rats pretreated with SSas exhibited peak GH responses following hexarelin or GHRP-6 of 702 +/- 115 and 312 +/- 42 ng/ml, respectively. These plasma GH responses were similar to those observed in the CTLas-pretreated animals.(ABSTRACT TRUNCATED AT 250 WORDS)
    2 context sentences
    Summary · context
    Animals were then treated i.v. with 25 micrograms/kg of either hexarelin or GHRP-6 4 h after i.v. antisera pretreatment.
    Summary · context
    In the present study, we have examined the neuroendocrine mechanism by which hexarelin and GHRP-6, two GH-releasing peptides, mediate their actions.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  2. 04AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome

    In rats pretreated with somatostatin antiserum, the peak GH response to GHRP‑6 was similar to that in control antiserum rats.

    In plain wordsIn rats given somatostatin antiserum, GHRP‑6 raised growth hormone about as much as in rats given control antiserum.

    Peptide
    GHRP-6
    Outcome
    No significant changePeak plasma GH after GHRP-6, somatostatin antiserum pretreatment
    Study

    ratn: not reported in source

    Adult male rats with jugular catheters
    Comparator
    Control antiserum pretreatment
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Peak plasma GH
    312 ng/ml
    GHRP-6 after somatostatin antiserum

    Source sentences

    Summary
    Rats pretreated with SSas exhibited peak GH responses following hexarelin or GHRP-6 of 702 +/- 115 and 312 +/- 42 ng/ml, respectively. These plasma GH responses were similar to those observed in the CTLas-pretreated animals.(ABSTRACT TRUNCATED AT 250 WORDS)
    2 context sentences
    Summary · context
    Animals were then treated i.v. with 25 micrograms/kg of either hexarelin or GHRP-6 4 h after i.v. antisera pretreatment.
    Summary · context
    In the present study, we have examined the neuroendocrine mechanism by which hexarelin and GHRP-6, two GH-releasing peptides, mediate their actions.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 2

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.